Welcome to our dedicated page for Pharmacyte Biotech news (Ticker: PMCB), a resource for investors and traders seeking the latest updates and insights on Pharmacyte Biotech stock.
Pharmacyte Biotech Inc (PMCB) is a clinical-stage biotechnology company advancing targeted cellular therapies for cancer and diabetes through its patented Cell-in-a-Box® platform. This page serves as the definitive source for PMCB news, offering investors and researchers verified updates on clinical progress and scientific breakthroughs.
Access timely reports on clinical trial milestones, regulatory developments, and research collaborations directly impacting PMCB's therapeutic pipeline. Our curated collection includes press releases on treatment efficacy studies, technology patents, and strategic partnerships essential for evaluating the company's trajectory.
Key updates cover advancements in localized cancer therapies for pancreatic tumors and encapsulated cell treatments for insulin regulation. Monitor critical developments in live-cell encapsulation technology and its applications across PMCB's oncology and metabolic disorder programs.
Bookmark this resource for structured access to PMCB's scientific progress. Check regularly for objective reporting on preclinical results, FDA communications, and peer-reviewed research publications central to the company's clinical-stage operations.
PharmaCyte Biotech (Nasdaq:PMCB) has increased its investment in TNF Pharmaceuticals (Nasdaq:TNFA) by $3 million to support TNF's recent licensing agreement with LightSolver. The investment backs LightSolver's revolutionary processing accelerator technology, which uses light for computation to achieve 90% energy reduction while delivering superior performance compared to conventional computing methods.
The technology is planned for cryptocurrency mining and blockchain applications. TNF plans to change its name and ticker symbol to align with this new strategic direction. PharmaCyte maintains a strong financial position with total assets exceeding $55 million as of April 30, 2025, and continues to explore additional investment opportunities.
PharmaCyte Biotech (Nasdaq:PMCB) has successfully closed a $7 million financing. The company's financial position shows approximately $15.5 million in cash and over $30 million in securities as of April 30, 2025. With this new financing, PharmaCyte aims to strengthen its balance sheet and support ongoing business initiatives.
The company, under Interim CEO Josh Silverman's leadership, maintains a reduced operational burn rate and plans to use the capital to advance initiatives and evaluate strategic opportunities. Currently, PharmaCyte has approximately 6.8 million shares of common stock outstanding.
PharmaCyte Biotech (Nasdaq:PMCB) has secured a $7 million private placement from existing investors through the sale of Series C convertible preferred stock. The financing includes 7,000 shares of preferred stock at $1,000 per share, convertible into 7 million common shares, along with warrants to purchase an additional 7 million shares.
The preferred stock features a $1.00 conversion price and a 7.0% quarterly cash dividend. The warrants are immediately exercisable at $1.00 per share with a five-year term. The transaction, expected to close around August 19, 2025, was priced at a premium to the current market price and will be conducted as a private placement through GP Nurmenkari Inc.
MyMD Pharmaceuticals has secured up to $42 million in strategic investments through two private placement funding rounds. The first round raised $7 million from PharmaCyte Biotech, while the second round secured another $7 million from existing shareholders. These financings involve Series G and Series F-1 Preferred Stock, both convertible to MYMD common stock, with accompanying warrants. The closings are anticipated around May 22, 2024. The Series G Preferred Stock includes 7,000 shares with a $1,000 per share value, and Series F-1 includes 5,050 shares. The funds are expected to support MyMD's clinical studies on MYMD-1 for sarcopenia over the next two years. The full conversion and warrant exercise are subject to stockholder approval.
PharmaCyte Biotech has announced a $7 million strategic investment in MyMD Pharmaceuticals, a company focused on treating inflammatory diseases, age-related conditions, and autoimmune disorders. This investment is part of PharmaCyte's strategy to leverage its $65 million cash position to enhance stockholder value. MyMD's lead product, MYMD-1, has shown promising results in a Phase 2 clinical trial for sarcopenia, and the company plans to move forward with further clinical studies in collaboration with the FDA. Both companies express optimism about the potential for future collaboration and the benefits of combining their expertise and resources.
PharmaCyte Biotech (NASDAQ:PMCB) has announced a second share repurchase program, authorizing up to $10 million to buy back its outstanding common stock over the next two years. The program will be funded through available cash, following a similar program initiated in June 2022. CEO Josh Silverman emphasized the company’s commitment to enhancing shareholder value while prudently managing expenses. The buyback may occur through various means, depending on market conditions and regulatory limitations, with no obligation to acquire a specific number of shares. This move reflects the company's strong financial position and potential strategic planning.
FAQ
What is the current stock price of Pharmacyte Biotech (PMCB)?
What is the market cap of Pharmacyte Biotech (PMCB)?
